


26/05/2015 02:55 p.m.

cc: bcc:

Subject: Fw: Pharmacovigilance Guideline



From:

Devices/MOH

To:

Mike Thompson <mike.thompson@paradise.net.nz>,

Cc:

Devices <devices@moh.govt.nz>

Date:

26/05/2015 12:10 p.m.

Subject:

Re: Pharmacovigilance Guideline

Sent by:

Dear Mike,

Thank you for your feedback on the guidance.

I have passed your comments on to the Clinical Risk Team.

Kind regards,

Medsafe
Clinical Leadership, Protection & Regulation

Ministry of Health DDI: 04 819 6800 Fax: 04 819 6801

http://www.medsafe.govt.nz mailto:devices@moh.govt.nz

## Mike Thompson

26/05/2015 11:13:58 a.m.

From:

Mike Thompson <mike.thompson@paradise.net.nz>

To:

Devices <devices@moh.govt.nz>,

Date:

26/05/2015 11:13 a.m.

Subject:

Pharmacovigilance Guideline

As mentioned on the phone, the draft PV guideline (consultation deadline was 15<sup>th</sup> May) is titled 'Therapeutic Products' but relates only to medicines, not medical devices. Either the title should be changed, or devices included as a sub-section. For completeness, the latter is preferable in my view.

## Kind regards,

## Mike

Mike Thompson | Ethos Consulting Group

ē'thos n. distinctive character, spirit, attitude...

33 Old Hautere Road, Te Horo, RD2 Otaki 5582, New Zealand

Phone: (+64) 6 364 3913 | Mobile: (+64) 21 364 391 | E-mail: mike.thompson@paradise.net.nz

This message may contain confidential and/or legally privileged information, intended only for the use of the addressee(s). If you are not the intended recipient, you may not use, disclose, copy or distribute the information. Please immediately notify the sender and destroy the document. Thank you.

Pharmacovigilance guideline - Medsafe consultation (draft 20Mar15).pdf